Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline, were re-randomized 1:1:1 to batoclimab (340mg weekly ...
Zacks Investment Research on MSN13d
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite SuccessImmunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia ...
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to focus on another next-gen asset for the indication.
The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.
Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and initial results from Period 1 of its Phase 2b study in chronic inflammatory ...
Clinical Trials Arena on MSN14d
Immunovant will not seek approval for MG therapy, despite hitting endpointsThe company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over the trial’s batoclimab.
Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline, were re-randomized 1:1:1 to batoclimab (340mg weekly ...
Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline, were re-randomized 1:1:1 to batoclimab (340mg ...
Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline, were re-randomized 1:1:1 to batoclimab (340mg ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback